Agonistic anti-DR5 antibodies, alone or in combination with other treatment modalities, show promising activity towards a variety of cancer types, including malignant melanoma. However, the therapeutic efficacy of current anti-DR5 antibodies is potentially limited as they indiscriminately interact with DR5 that is broadly present on normal cells. Therefore, we developed a novel bispecific antibody-based approach that promotes melanoma-directed pro-apoptotic activation of DR5. We engineered a novel recombinant bispecific antibody, designated MCSPxDR5, with both high binding affinity for the melanoma-associated antigen MCSP and potent agonistic activity towards DR5. The mode of action of MCSPxDR5 involves high-affinity binding to tumor cell surface-expressed MCSP with concomitant localized enhanced cross-linking of DR5.
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INTRODUCTION
Malignant melanoma is the most lethal type of skin cancer and its incidence continues to increase at an alarming rate 1 . The preferred curative option for early-stage localized melanoma is radical removal of the lesion, which results in excellent survival rates 2 . Currently ipilumumab (CTLA4 blockade), vemurafenib, dabrafenib, and high-dose IL-2 are used as first line agents for Stage IV melanoma. Newly emerging treatment options include checkpoint inhibitors including nivolumab (PD-1 blockade) and atezolizumab (PD-L1 blockade), oncolytic vaccines (talimogene laherparepevec), adoptive T cell therapies and dendritic cell vaccines 3 . In this respect, Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) also appears to be a promising anticancer agent as it induces apoptosis in a wide range of refractory malignancies including melanoma 4 . TRAIL is an immune effector protein that induces apoptosis in virus-infected cells and cancer cells by activating death receptor-4 (DR4) and/or death receptor-5(DR5) without deleterious activity towards DR4/DR5-expressing normal cells1 13 . Consequently, DR4/DR5 agonists have been regarded as promising anticancer agents. Indeed, treatment with "first-generation" DR4/DR5-targeted therapeutics, such as recombinant human soluble tumor necrosis factor related apoptosis-inducing ligand (rhTRAIL) and agonistic DR4/DR5 antibodies was well tolerated 5 . However, in a phase I dose-escalation study in patients with relapsed or refractory carcinoma the DR5-agonistic antibody tigatuzumab showed only limited clinical activity inducing stable disease in only selected patients 6 . Further, in a phase II trial in non-small cell lung cancer patients, combined treatment with rhTRAIL and chemotherapy had no added benefit over chemotherapy treatment alone 7 . However, advances in the understanding of death receptor signaling revealed that first-generation DR4/DR5 agonists do not fully exploit the unique signaling characteristics of TRAIL receptor-mediated cancer cell death 4, 8 . Specifically, DR4 and DR5 have distinct cross-linking requirements for the induction of apoptosis. DR4 is activated upon binding of rhTRAIL (or conventional DR4 antibodies), whereas apoptotic DR5 signaling requires membrane-bound TRAIL or secondarily cross-linked rhTRAIL 8 . Similarly, to gain therapeutic activity, agonistic DR5 antibodies such as tigatuzumab appear to require crosslinking by Fcɣ receptors as present on myeloid effector cells 11, 12 . Further, rhTRAIL and conventional agonistic DR4/5 antibodies have no tumor-selective binding activity, whereas TRAIL receptors are ubiquitously expressed on normal tissue 13 . Consequently, their efficacy may be hampered by a massive sink of normal healthy cells. As a result, relatively high concentrations of agonistic anti-DR5 mAbs are needed to overcome the target antigen sink formed by DR5 expressed on normal cells. Therefore, we engineered a recombinant bispecific antibody, designated MCSPxDR5, with both high binding affinity for Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP) and potent agonistic activity towards DR5. MCSP (also called CSPG4, NG2, HMW-MAA, MSK16, MCSPG, MEL-CSPG, or gp240) 14 is highly overexpressed on the cell surface of over 90% of cutaneous and uveal melanomas and is a well-established target for melanoma immunotherapy [14] [15] [16] [17] .
In normal tissues MCSP expression is predominantly restricted to cells of the melanocyte lineage. MCSPxDR5 was designed to selectively bind with high affinity to tumor cell surface-expressed MCSP and to concomitantly trigger localized activation of apoptosis by DR5 cross-linking. To the best of our 41 dialyzed fetal calf serum (dFCS), supplemented with 500 μg/ml hygromycin. Primary malignant melanoma cells were obtained from patients after informed consent. Human cells were cultured in either RPMI 1640 or DMEM culture medium with 10% FCS at 37°C in a humidified 5% CO 2 atmosphere. Cells lines were authenticated by commercial Short Tandem Repeat analysis and routinely tested for mycoplasma infection.
Primary human hepatocytes (PHH)
Cryopreserved human hepatocytes were purchased from Tebu-bio bv, Heerhugowaard, Netherlands. The hepatocytes were seeded in a 48 well plate at a density of 2.5x10 4 cells per well and cultured for 16 h before use.
Analysis of cell surface expression of DR5 and MCSP
Cell surface expression levels of DR5 and MCSP were assessed by flow cytometry. In short, cells were harvested and washed with PBS and re-suspended at 1×10 5 cells in 200 μl fresh culture medium containing anti-DR5 MAb (DJR2-4) or MAb 9.2.27 according to the manufacturer's recommendations. Specific binding of these antibodies was detected using secondary conjugated antibodies (FITCconjugated for DR5 staining and APC-conjugated for MCSP staining). All antibody incubations were carried out for 45 min at 0°C and were followed by 3 times washes with PBS.
Construction of MCSPxDR5 of human IgG1 and IgG4 isotype variants
scFvMCSP was constructed using published VH and VL sequence data of MAb 9.2.27 by applying standard antibody engineering technologies. ScFvDR5 was constructed using published VH and VL sequence data of agonistic anti-DR antibody tigatuzumab. For construction and production of MCSPxDR5 we used eukaryotic expression plasmid pEE14-bsAb (sup. data A), which is equipped with an enhanced CMV promoter to drive recombinant protein expression and an N-terminal leader peptide for excretion of MCSPxDR5 protein in the culture medium. The pEE14-bsAb contains 3 consecutive multiple cloning sites (MCS#1, MCS#2 and MCS #3, respectively). MCS#1 and MCS#2 are interspersed by a 22 amino acid flexible linker derived from a CH1 domain. MCS#1 was used for directional and in-frame insertion of the scFvDR5 encoding DNA fragment. MCS#2 was used for directional and in-frame insertion of the scFvMCSP encoding DNA fragment. MCS#3 of pEE14-bsAb was used for inframe insertion of DNA fragments encoding either human IgG 1 or IgG 4 domain. Of note, hinge regions and flexible spacers were inserted between the different antigen recognizing parts of bsAb to allow each part of the molecule to function independently. Moreover, the codon usage of the various protein encoding DNA sequences mentioned above were optimized for expression in human (HEK) and hamster (CHO) production cell lines and were ordered from a certified gene synthesis services (Genscript, Piscataway, NJ, USA). This procedure yielded plasmids pEE14-MCSPxDR5 and the corresponding IgG 4 isotype variant pEE14-MCSPxDR5-IgG4.
Production of bsAb MCSPxDR5 in CHO cells
Plasmids pEE14-MCSPxDR5 and pEE14-MCSPxDR5-IgG 4 were stably transfected in CHO production cells, after which clones with amplified recombinant protein production (10 μg/ml and 7 μg/ml for MCSPxDR5 and MCSPxDR5-IgG4, respectively) were selected essentially as described previously 18 . Molecular weights of bsAb MCSPxDR5 and MCSPxDR5-4 were assessed by SDS-PAGE and subsequent immunoblot analysis. Both proteins showed the expected apparent MW of approximately 150-170 kDA (Sup.data B). Concentrations of MCSPxDR5 and MCSPxDR5-IgG4 were determined using the Human Easy-Titer kit according the manufacturer's recommendations (Thermo Scientific).
MCSP-selective binding of MCSPxDR5
MCSP-selective binding of MCSPxDR5 was assessed by flow cytometry using CHO.MCSP cells and MCSPneg parental CHO cells. In short, cells were harvested and washed with PBS. Subsequently, cells were incubated with MCSPxDR5 (1 µg/ml) in the presence or absence of an excess amount of the competing parental anti-MCSP antibody MAb 9.2.27 (10 µg/ml). Detection of cell surfacebound MCSPxDR5 was analyzed by flow cytometry using anti-human IgG 1 -PE.
MCSP-directed induction of apoptosis by MCSPxDR5
A panel of MCSP pos and MCSP neg tumor cell lines was subjected to treatment with MCSPxDR5. Briefly, tumor cells were seeded in 48-well plates at a concentration of 2x10 4 cells/well. Subsequently, tumor cells were treated with MCSPxDR5 (1 µg/ml) overnight after which apoptosis was assessed. Alternatively, tumor cells were treated with MCSPxDR5 (2.5 µg/ml) on ice for 40 min after which unbound MCSPxDR5 was removed by washing twice with cold PBS and then cultured overnight. To determine toxicity of MCSPxDR5 to normal cells, human hepatocytes, lymphocytes, granulocytes and HUVECs were harvested and treated with MCSPxDR5 (2.5 µg/ml) overnight.
Assessment of synergy between MCSPxDR5 and clinical antitumor drugs
MCSP pos /DR5 pos melanoma cell lines (A375M, MM-RU and OCM-3) were treated with MCSPxDR5 (0.25 μg/ml) in the presence or absence of proteasome inhibitor velcade (1 nM), HDAC inhibitor VPA (2.5 μM) or BRAF-inhibitor vemurafenib (10 μM). After 18h treatment, apoptosis was assessed as indicated below. Synergy was determined using the cooperativity index (CI), in which the sum of apoptosis induced by single-agent treatment is divided by apoptosis induced by combination-treatment. When CI<1, treatment was termed synergistic.
Assessment of apoptosis induction
Apoptosis was evaluated by one or more of the following assays; Loss of mitochondrial membrane potential (∆): after treatment tumor cells were harvested by centrifugation (1000xg, 5 min) and incubated for 20 min with 0.1 M DiOC6 (Molecular Probes, Eugene, OR) at 37°C. Next cells were pelleted by centrifugation, re-suspended in PBS and evaluated by flow cytometry. Phosphatidylserine (PS) cell surface exposure; early-stage apoptosis was analyzed by Annexin-V staining method according to manufacturer's protocol (Immunotools). Cells were harvested and washed once with cold binding buffer (140 mmol/L NaCl, 2.5mmol/L CaCl 2 and 10 mmol/L HEPES, pH 7.4). Next, cells were resuspended in binding buffer containing Annexin-V-FITC. After incubation for 10-15 minutes at 4°C, PS exposure was determined by flow cytometry. Cell viability assay; tumor cell viability was assessed by a standard MTS assay (Promega Benelux, Leiden, Netherlands). Briefly, cells were seeded in a flat-bottom 96-well micro culture plate at a density of 2×10 4 cells per well in 200 μl culture medium. After overnight culture, spent medium was removed and replaced by 200 μl medium containing the various experimental conditions. Cell viability was assessed after 48 h of treatment. Each experimental and control group was performed in triplicate.
Colony forming assay
In short, a single-cell suspension of tumor cells was prepared in 0.6% low gelling temperature (LGT) agarose dissolved in pre-warmed complete medium (RPMI 1640 with 20 % FCS). Tumor cells (1.0x10 4 cells per well) were placed in 24well plates containing a bottom layer of solidified 4%
LGT agarose in complete medium. Once the tumor cell-containing agarose top layer had solidified, a final 0.5 ml of complete medium was added. In this assay, MCSPpos melanoma cells A375M, SK-MEL-28, MM-RU and HT1080 were treated with MCSPxDR5 (final concentration up to 250 ng/ml) for 14 days, after which colony formation was evaluated by light microscopy. In control experiments identical treatment was performed in the presence of an excess amount of TRAIL-R2-Fc (5 µg/ ml) or the pan-caspase inhibitor zVAD-fmk (10 μM). Colony forming assays were performed in quadruplicates. The number and size of colonies were quantified using image processing software (ImageJ). The percentage of colony formation was calculated according to the formula: percentage of colonies formed = (number of colonies in experimental condition) / (number of colonies in medium control) x 100%. For medium treated A375M cells the number of colonies formed ranged between 60 to150.
siRNA-mediated knockdown of DR5 expression
SK-MEL-28 cells were seeded in 12-wells plates at a concentration of 1x10 5 cells/well, cultured overnight, and treated with either DR5-selective siRNA or scramble siRNA according to manufacturer's recommendations. siRNA knockdown DR5 protein expression was evaluated after 72 h by flow cytometry using anti-DR5 antibodies. Antibody incubations were carried out for 45 min at 0°C and were followed by 3 washes with PBS. Subsequently, DR5-silenced SK-MEL-28 cells were seeded and subjected to treatment as indicated.
Assessment antitumor activity upon cross-linking of MCSPxDR5
The following assays were used to assess whether MCSP-directed pro-apoptotic activity of MCSPxDR5 towards cancer cell lines and primary patient-derived melanoma cells could be further enhanced by secondarily cross-linking of its IgG 1 Fc domain. In short, cancer cells were seeded at 3x10 4 /well in 96well microculture plate and subsequently treated with increasing doses of MCSPxDR5 in the presence or absence of an Fc crosslinker (0.5 µg/ml of goatanti-human IgG), hereafter indicated as CL. Apoptosis and (loss) of tumor cell viability were evaluated after 24h and 72h, respectively. To investigate whether the observed apoptotic activity of MCSPxDR5 is dependent on DR5 signaling, MM-RU cells were seeded at 3x104 /well and subsequently co-treated with MCSPxDR5 and CL in the presence or absence of recombinant TRAILR2-Fc (5 µg/ml) or pan-caspase inhibitor zVADfmk (5 µM) for 24h. Additionally, we used MCSPpos SK-MEL-28 melanoma cells in which DR5 expression was knockeddown using DR5-specific siRNA silencing technology according to our previous study59. Subsequently, DR5-silenced SK-MEL-28 cells and wt SK-MEL-28 cells were treated with MCSPxDR5 (1 µg/ml) or anti-TRAILR2 monoclonal antibody HGT-ETR2 (1 µg/ml) after which apoptosis was evaluated as indicated above.
To mimic cell-based Fc cross-linking of MCSPxDR5, we used HEK293.CD64 cells ectopically expressing human CD64, al so known as the high-affinity IgG receptor FcγRI. In short, DiD-labeled MM-RU cells were co-cultured with HEK293.CD64 cells at a cellular ratio of 5 to 1 in the presence or absence MCSPxDR5 (250 ng/ml). After 24h of treatment, apoptosis in DiD-labeled MM-RU cells was evaluated. Analogously, various myeloid effector cells (peripheral blood mononuclear cells (PBMCs), leukocytes (WBCs) or NK cells) were used as natural cell-based Fc cross-linkers123 of MCSPxDR5. In short, DiD-labeled MM-RU target cells were treated (or not) with MCSPxDR5 in the presence of various ratios of myeloid effector cells (E:T cell ratios were 20:1, 5:1 and 20:1 for PBLs, WBCs and NK cells, respectively). To discriminate ADCC from DR5-cross-linking antitumor activity we used MCSPxDR5-IgG4, a human IgG4-isotype variant of MCSPxDR5 that has only marginal ADCC activity 20 .
Statistical analysis
The results reported in this study are mean values ± standard error of the mean of at least three independent experiments. Statistical analysis was performed by one-way ANOVA followed by Tukey-Kramer post-test or by two-sided unpaired Student's t-test. p<0.05 was defined as a statistically significant difference.
RESULTS

MCSPxDR5 has MCSP-directed pro-apoptotic activity
BsAb MCSPxDR5 was designed to bind to MCSP on cancer cells and subsequently to induce apoptosis in targeted cancer cells by local ligation of DR5. In line with this, flow cytometric analysis showed that MCSPxDR5 strongly bound to MCSP pos /DR5 pos SK-MEL-28 melanoma cells ( Fig.1B) , but not to MCSP neg / DR5 pos DLD-1 carcinoma cells (Fig.1C ). Binding of MCSPxDR5 to SK-MEL-28 cells was blocked by co-incubation with excess amounts of epitope-competing anti-MCSP mAb 9.9.27 ( Fig.1B) , indicating that MCSPxDR5 indeed selectively binds to cell surface-expressed MCSP. Correspondingly, treatment of tumor cells incubated with MCSPxDR5 for 40 minutes at 4°C, after which any unbound antibody was removed by washing, melanoma cells, but not in MCSP neg /DR5 pos HCT116 carcinoma cells ( Fig.1D ). Similar treatment in the continued presence of MCSPxDR5 (no washing) induced apoptosis in both MCSP pos /DR5 pos and MCSP neg /DR5 pos cancer cells ( Fig.1E ), albeit in latter cancer cells at much lower levels. MCSPxDR5 treatment was associated with reduced tumor cell viability in MCSP pos /DR5 pos MM-RU, SK-MEL-28 and OCM3 cells, but not in MCSP pos /DR5 neg DLD-1 cells (Fig.1F ). MCSP-selective pro-apoptotic activity of MCSPxDR5 was also evaluated using primary patient-derived melanoma samples that were phenotyped for MCSP and DR5 expression ( Fig.1G ). MCSP pos primary tumor cells derived from melanoma patients proved sensitive to MCSPxDR5 treatment, with an >40% increase in apoptosis compared to medium control (Fig.1H) . Thus, MCSPxDR5 selectively binds to MCSP and has MCSP-directed pro-apoptotic activity towards MCSP pos /DR5 pos cancer cell lines and MCSP pos /DR5 pos primary patient-derived melanoma cells.
MCSPxDR5 inhibits colony forming capacity of MCSP pos /DR5 pos cancer cells
Next, the effect of MCSPxDR5 on anchorage-independent growth of MCSP pos melanoma was evaluated using a soft agar colony forming assay. Treatment with MCSPxDR5 for 14 days led to a significant reduction in colony number in MCSP pos melanoma cell lines (A375M, SK-MEK-28, MM-RU) ( Fig. 2A) . Further, as illustrated for A375M, bright-field microscopy revealed that any residual colonies of A375m cells after MCSPxDR5 treatment were reduced in size by >90% ( Fig.2B ). Of note, this MCSPxDR5-mediated effect was completely blocked either by cotreatment with recombinant anti-TRAILR2-Fc or by pan-caspase inhibitor zVADfmk, indicating that the pro-apoptotic activity of MCSPxDR5 is caspase-mediated and dependent on DR5 ( Fig.2C ). Of note, MCSPxDR5 also reduced colony number of MCSP pos /DR5 pos HT1080 sarcoma cells by ~90%, whereas control non-targeted anti-DR5 antibody HGS-ETR2 only reduced colony number by ~50% ( Fig.2D ). Taken together, MCSPxDR5 inhibited colony forming capacity of MCSP pos /DR5 pos cancer cells.
Efficacy of MCSPxDR5 is enhanced by cross-linking of its Fc domain
MCSPxDR5 was designed to trigger apoptosis through MCSP-directed crosslinking of DR5. It has been reported that in vivo the antitumor activity tigatuzumab requires cross-linking of its IgG 1 Fc domain through binding to MCSPxDR5 alone did not induce apoptosis. However, upon secondary crosslinking MCSPxDR5 strongly induced apoptosis in Jurkat cell up to almost 100%, with apoptotic activity of MCSPxDR5 already apparent at doses as low as 5 ng/ml (Fig.3A) . Similarly, secondary cross-linking of MCSPxDR5 enhanced its pro-apoptotic antitumor activity and in a panel of MCSP pos /DR5 pos melanoma cell lines ( Fig.3B and 3C, respectively) . Importantly, secondary cross-linking of MCSPxDR5 also increased the level of apoptosis induced in primary patientderived melanoma cells, with a mean increase in apoptosis from 48% to 70% (Fig.3D) . Again, MCSPxDR5 activity was abrogated by cotreatment with recombinant DR5-Fc or pan-caspase inhibitor zVADfmk, as illustrated for the melanoma cell lines MM-RU ( Fig.3E) . Moreover, siRNA-mediated DR5 silencing in A375M cells strongly reduced the apoptotic activity of both MCSPxDR5 and the DR5-agonistic antibody HGS-ETR2 ( Fig. 3F and 3G) . Thus Fc-mediated crosslinking augments the pro-apoptotic antitumor activity of MCSPxDR5 through enhanced DR5 signaling. (Fig.4B) . Importantly, Fc receptor cross-linking also induced MCSP-independent DR5mediated activation in MCSP neg /DR5 pos melanoma M14 cells (Fig.4C ). However, Fc receptor-mediated cross-linking on MCSP pos cells was abrogated when treatment was performed in the presence of MCSP-competing mAb 9.9.27 (Fig.4D ). In analogous mixed culture experiments with freshly isolated PBLs, MCSPxDR5 induced a dose-dependent reduction of cell viability to 40% at an E:T ratio of 20:1 (Fig.4E) . Moreover, treatment with an increasing dose of MCSPxDR5 reduced cell viability of MM-RU cells to 20% at a 5:1 E:T ratio with leukocytes ( Fig.4F) . Similarly, MCSPxDR5 significantly enhanced NK cellmediated killing of MCSP pos /DR5 pos A375M cells, but not of MCSP neg /DR5 pos DLD1 cells (Fig.4G) . Thus, the MCSP-directed pro-apoptotic activity of MCSPxDR5 is further augmented by FcR-mediated cellular cross-linking and is able to induce ADCC through interaction with Fc receptor-expressing immune effector cells. (Fig.5A ). Moreover, treatment of primary HUVECs, lymphocytes and granulocytes with MCSPxDR5 (2.5 µg/ml) did not induce apoptosis (Fig.5B) . Thus, these data indicate that MCSPxDR5 induces tumoricidal activity with no or only limited toxicity toward normal cells. This is in line with a previous phase I clinical study that showed that tigatuzumab was well-tolerated with no doselimiting toxicity (DLT) reached with no-drug-related grade 3 or 4 hepatic or hematological toxicity observed 23 .
Efficacy of MCSPXDR5 is augmented by FcR-mediated cross-linking
MCSPxDR5 shows no or limited toxicity toward normal cells
Anticancer drugs synergize anticancer activity of MCSPxDR5
Melanoma-relevant drugs (bortezomib, valproic acid and vemurafenib) were evaluated for their potency to synergize the antitumor activity of MCSPxDR5. Co-treatment of MCSP pos /DR5 pos melanoma cells with MCSPxDR5 and velcade triggered synergistic induction of apoptosis in A375M and MM-RU cells (52%, A375M; 80%, MM-RU) but not in OCM-3 cells (Fig.6A ). MCSPxDR5-mediated apoptosis was synergized by HDAC inhibitor VPA increased to 62% in A375M cells compared to single treatment with MCSPxDR5 or VPA. Similarly, synergistic effect with VPA was also observed in MM-RU and SK-MEL-28 cells (40%, MM-RU; 38%, SK-MEL-28) ( Fig.6B ). Interestingly, we found vemurafenib not only enhanced MCSPxDR5-mediated apoptosis in V600-mutant melanoma cell lines OCM-3 and SK-MEL-28 (54%,SK-MEL-28; 86%,OCM-3), but also increased MCSPxDR5-induced apoptosis to 60% in V600-wide type melanoma cell line MM-RU compared to single treatment with MCSPxDR5 ( Fig.6C ).
Discussion
Recombinant TRAIL formulations (e.g. dulanermin) and agonistic anti-DR4/5 antibodies (e.g. conatumumab and tigatuzumab, respectively) have been extensively evaluated in pre-clinical and clinical studies [24] [25] [26] . Results from earlystage clinical studies indicated that both recombinant TRAIL and agonistic anti-DR antibodies are well-tolerated in patients with various cancers. However, the therapeutic efficacy of current DR agonist is rather disappointing. This appears to be related to the fact that these agonists indiscriminately interact with DRs that are broadly present on normal cells 23, 27 , thereby precluding sufficient accumulation of the agonist in malignant lesions, and by the fact that these agents have limited capacity to activate pro-apoptotic DR5 signaling in cancer cells. Therefore, we developed a novel bispecific antibody-based approach that promotes melanoma-directed pro-apoptotic activation of DR5. To this end, we engineered a novel recombinant bispecific antibody MCSPxDR5 that has both high binding affinity for the melanoma-associated antigen MCSP and potent agonistic activity towards DR5. The mode-of-action of MCSPxDR5 involved high-affinity binding to tumor cell surface-expressed MCSP with 21, 22 . However, MCSPxDR5 selective binding to MCSP already can trigger effective activation of membrane DR5 in melanoma, indicating that on MCSP pos target cells MCSPxDR5 can at least partly circumvent the need for FcRmediated cross-linking. Importantly, the antitumor activity of MCSPxDR5 could be further enhanced by FcR-expressing immune effector cells, through FcRmediated cross-linking as well as induction of ADCC. Recently, a similar DR5-targeted bi-specific antibody, RG7386, targeting the fibroblast-associated protein (FAP) on cancer-associated fibroblasts was reported 26 . Similar to our findings, RG7386 induced apoptosis in target antigenpositive cells and, when combined with irinotecan or doxorubicin, induced tumor regression in patient-derived xenograft models 26 . Our data largely corroborates these observations, indicating a common mode-of-action for RG7386 and MCSPxDR5. Melanoma-associated chondroitin sulfate proteoglycan (MCSP), also called CSPG4 or HMW-MAA, is expressed in 90% of melanoma lesions 27 and other malignancies, e.g. sarcomas and gliomas 27,28 plays a significant role in melanoma progression by influencing adhesion/spreading, migration, invasion, and metastasis. It has been reported that binding to MCSP by mAb 9.2.27 already in its own right can partly inhibit various oncogenic features of MCSP expression. Indeed, we previously reported on a MCSP-targeting TRAIL fusion protein, designated scFvMCSP:TRAIL, that not only induce MCSP-directed TRAILmediated apoptosis in melanoma cells, but also inhibited MCSP-mediated tumorigenic signaling 9 . The MCSP-directed antibody fragment used in bsAb MCSPxDR5 is derived from mAb 9.2.27. Although not formally studied here, it is tentative to speculate that bsAb MCSPxDR5 may have retained the potential to (partly) inhibited MCSP-tumorigenic signaling that may add to or even synergize its pro-apoptotic anticancer activity. Studies to evaluate this additional anticancer activity of MCSPxDR5 are under way. Co-treatment of agonistic anti-DR5 antibodies or soluble TRAIL with various chemotherapeutics or (experimental) small inhibitory molecules has been evaluated in order to mutually augment their antitumor activities towards various forms of cancer, including carcinoma, breast cancer, lung cancer and metastatic melanoma 6, 7, 24, 30, 31 . In our study, we found that co-treatment of HDAC inhibitor VPA synergized the pro-apoptotic anticancer activity of MCSP in MCSP pos /DR5 pos melanoma cells. This synergistic enhancement is likely attributable to the fact that HDAC inhibitors are known to down-regulate C-FLIP and thereby increase sensitivity to treatment of DR5-based agonists 32 . Interestingly, we found BrafV600E inhibitor vemurafenib enhanced MCSPxDR5induced apoptosis in both wide-type and V600-mutant melanoma cells. This non-specific synergy with vemurafenib and TRAIL was also published by others but the reason remains unclear so far 33 . Our current in vitro data indicates that MCSPxDR5 has potent MCSP-directed pro-apoptotic activity towards MCSP pos /DR5 pos melanoma cells with essentially no or minimal toxicity towards various normal cells. However, more in-depth studies are needed to establish whether this will also translate in a safe toxicity profile when applied in melanoma patients. Taken together, we present for the first time a bispecific antibody-based approach that promotes melanoma-directed pro-apoptotic activation of DR5. This novel approach may be of value for the targeted treatment of melanoma and other MCSP-expressing malignancies.
